Giant-cell arteritis and polymyalgia rheumatica.

Area of Science:

• Immunology
• Rheumatology
• Vascular Biology

Background:

• Giant-cell arteritis (GCA) is an immune-mediated disease affecting medium and large arteries.
• Pathology involves excessive cytokine production (e.g., interleukin-6) and T-cell mediated macrophage activation.
• Arterial intimal hyperplasia can lead to luminal occlusion and tissue ischemia.

Purpose of the Study:

• To outline the immunopathology and clinical manifestations of giant-cell arteritis.
• To describe diagnostic approaches for various GCA subtypes.
• To discuss current therapeutic strategies and future directions in GCA management.

Main Methods:

• Review of existing literature on giant-cell arteritis.
• Analysis of immunopathological mechanisms including cytokine involvement.
• Correlation of clinical presentation with affected vascular territories.
• Evaluation of diagnostic modalities like temporal artery biopsy and vascular imaging.
• Assessment of laboratory markers such as C-reactive protein and erythrocyte sedimentation rate.

Main Results:

• GCA presents with distinct clinical subtypes based on predominant vascular involvement (cranial, large-vessel, aortic, systemic, polymyalgia rheumatica).
• Diagnosis relies on temporal artery biopsy for cranial GCA and vascular imaging for other territories.
• Elevated acute-phase reactants (CRP, ESR) are characteristic; cytokines like IL-6 are explored as disease activity markers.
• Corticosteroids effectively suppress inflammation but do not resolve underlying immune responses.

Conclusions:

• Giant-cell arteritis is a complex immune-mediated vasculitis with diverse clinical presentations.
• Accurate diagnosis requires a combination of clinical suspicion, imaging, and laboratory findings.
• While corticosteroids are effective, individualized treatment strategies are crucial for optimal patient outcomes, focusing on managing immune responses within the vessel wall.